Target intelligence / Profile preview

Ribonucleoside-diphosphate reductase large subunit (RRM1)

Target
RRM1
Molecular classification
Enzyme, Oxidoreductase
01

Overview

Ribonucleoside-diphosphate reductase large subunit (RRM1) is the catalytic and regulatory subunit of ribonucleotide reductase (RNR), a key enzyme that catalyzes the rate-limiting conversion of ribonucleoside diphosphates (NDPs) to deoxyribonucleoside diphosphates (dNDPs). This process is essential for maintaining balanced deoxyribonucleotide (dNTP) pools required for de novo DNA replication and repair. RRM1 contains a catalytic site (C-site) and two distinct allosteric regulatory sites: the activity site (A-site), which controls overall enzyme activity, and the specificity site (S-site), which regulates substrate preference. Binding of ATP to the A-site activates the enzyme, whereas binding of dATP or certain nucleoside analog triphosphates (such as clofarabine triphosphate) induces the formation of inactive RRM1 hexamers, shutting down dNTP synthesis. Overexpression of RRM1 is strongly associated with resistance to nucleoside analog chemotherapies like gemcitabine, making its expression levels a critical predictive biomarker in various cancers, including non-small cell lung cancer and pancreatic cancer. Consequently, targeting the RRM1 allosteric site with small molecules or nucleoside analogs represents a powerful therapeutic strategy to deplete dNTP pools, disrupt DNA replication, and induce apoptosis in rapidly proliferating cancer cells.

Other names
Ribonucleotide reductase catalytic subunit M1Ribonucleoside-diphosphate reductase subunit M1Ribonucleotide reductase large subunitRibonucleotide reductase large chainR1RR1RIR1
02

Mechanism of action

Allosteric inhibition of ribonucleotide reductase by binding to the activity site (A-site) or specificity site (S-site) of the RRM1 subunit. This binding induces inactive hexamerization of the enzyme, depleting intracellular deoxyribonucleotide (dNTP) pools and halting DNA replication and repair.

03

Biological functions

Deoxyribonucleotide synthesisDNA replicationDNA repairCell cycleCell proliferation
04

Disease associations

CancerMitochondrial DNA depletion syndrome
05

Safety considerations

Myelosuppression (neutropenia, thrombocytopenia, anemia)ImmunosuppressionGastrointestinal toxicityHepatotoxicityNephrotoxicityMutagenicity and chromosomal instabilityChemotherapy resistance due to RRM1 overexpression
06

Interacting drugs

3 more in the full profile.

07

Biomarkers

RRM1 expression levelIntracellular dNTP pool levels

Beyond the preview

Go deeper on Ribonucleoside-diphosphate reductase large subunit (RRM1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribonucleoside-diphosphate reductase large subunit (RRM1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call